TTG isn’t just a bystander in celiac disease—it’s the molecular editor that makes gluten destructive.
Tissue transglutaminase (TTG) plays a central pathogenic role by deamidating gliadin peptides in the intestinal mucosa, transforming them into highly immunogenic epitopes. This chemical modification is what allows the immune system to recognize gluten as a threat, triggering T-cell activation, intestinal inflammation, and the production of disease-specific autoantibodies. Consequently, this mechanism directly dictates that IVD diagnostic kits must use recombinant TTG itself and deamidated gliadin peptides (DGPs) as capture antigens to detect the clinically relevant antibodies driving the disease.
Core Takeaway: TTG creates the very antigens that the immune system attacks. Therefore, a diagnostic assay that mirrors this pathology—by using recombinant TTG and deamidated gliadin peptides as targets—captures the precise disease-specific autoantibodies, delivering the high sensitivity and specificity required for reliable, non-invasive diagnosis.
The Pathophysiology: How TTG Sparks the Autoimmune Cascade
Gliadin Deamidation: The Critical First Step
In genetically susceptible individuals, dietary gluten arrives in the small intestine only partially digested. TTG, a ubiquitous intestinal enzyme, then acts on the gliadin component of gluten, converting specific glutamine residues into glutamic acid. This single chemical change—removing an amine group and adding a negative charge—is the pivotal event that transforms innocuous food peptides into potent immunogens.
The deamidation doesn’t just alter the peptide’s structure; it dramatically enhances its binding affinity to the disease-associated HLA-DQ2 and HLA-DQ8 molecules on antigen-presenting cells. Native, unmodified gliadin barely registers. The TTG-edited version, however, fits perfectly into the HLA binding groove, ensuring that the immune system sees it as a high-priority target.
From Modified Peptides to Autoantibodies
Once antigen-presenting cells display these deamidated gliadin peptides, they activate CD4 T lymphocytes, unleashing a cytokine-driven inflammatory response that damages the intestinal villi. Crucially, the same T-cell help drives B cells to produce not only anti-gliadin antibodies but also autoantibodies that target the modifying enzyme itself—TTG—as well as the endomysium. The body mistakenly turns its defensive machinery against its own enzyme, creating a durable serological footprint of the disease.
This dual autoantibody response (anti-TTG and anti-DGP) is the diagnostic gold mine. It reveals that the patient’s immune system is reacting to both the altered substrate (deamidated gliadin) and the catalyst (tissue transglutaminase), giving assay developers two orthogonal serological markers rooted in the same pathogenic pathway.
Translating Mechanism into Diagnostic Antigen Selection
Why Recombinant tTG is the Gold Standard
Because TTG is the central autoantigen, the most direct diagnostic strategy is to use purified TTG as the capture reagent in ELISA or chemiluminescence assays. The human recombinant form offers unparalleled purity and consistency, avoiding the batch-to-batch variability of native tissue extracts. IgA anti-tTG assays routinely achieve sensitivity exceeding 90% and specificity over 99%, making them the first-line screening test for celiac disease.
Using a standardized recombinant antigen also dramatically reduces cross-reactivity and the risk of false positives, which is critical when screening high-risk populations such as patients with type 1 diabetes or autoimmune thyroid disease. The assay directly mimics the in vivo target, thus capturing only antibodies that are pathophysiologically relevant.
Deamidated Gliadin Peptides: The Essential Second Target
The native gliadin molecule is a poor antigen—assays built on it suffer from low specificity, often yielding false positives in healthy individuals. Following the pathogenic logic, the diagnostic target must be the deamidated form of gliadin, which is the actual immunogenic product. Deamidated gliadin peptides (DGPs) offer a synthetic, defined alternative that replicates the TTG-modified epitopes.
IgA anti-DGP assays provide sensitivity of 85–90% and specificity approaching 95%, while IgG anti-DGP assays push specificity near 99%. This makes them invaluable complements. Notably, DGP-based tests perform exceptionally well in pediatric patients under three years of age, where anti-TTG responses may still be maturing. Incorporating DGP antigens alongside tTG creates a comprehensive safety net.
The Necessity of Dual IgA/IgG Testing
One of the most treacherous pitfalls in celiac serology is selective IgA deficiency, which occurs in approximately 1 in 600 individuals. These patients are completely unable to produce IgA antibodies, rendering any IgA-based test falsely negative, regardless of disease activity.
The pathology teaches us that the autoimmune B-cell response isn’t isotype-limited. Therefore, a well-designed IVD kit must include parallel IgG detection pathways—IgG anti-tTG and IgG anti-DGP—to catch these cases. Pairing this with a total IgA reference reagent ensures the lab can first identify an IgA deficiency and then correctly interpret the IgG results.
Avoiding Common Pitfalls in Assay Design
The Trap of Using Native Gliadin
Native gliadin assays are a relic of an older diagnostic era. Because the natural protein lacks the negative charges introduced by TTG, it displays inherently poor binding to the disease-associated HLA molecules and generates substantial non-specific binding. This results in unacceptably low diagnostic specificity, leading to overdiagnosis and unnecessary biopsies. Ignore native gliadin; the pathophysiological rationale and clinical data unequivocally support using deamidated gliadin peptides instead.
Managing Selective IgA Deficiency (the False-Negative Blind Spot)
Even a perfect IgA anti-tTG assay will miss every true celiac patient who is IgA deficient—a potentially catastrophic oversight. Without a simultaneous IgG-based test, these patients slip through the screening net. The solution is not optional but mandatory: any serious IVD screening kit must bundle both isotype-specific detection systems. Failing to offer dual IgA/IgG panels is the single most preventable error in celiac diagnostic kit development.
Making the Right Choice for Your Diagnostic Kit
Ultimately, the pathogen-driven antigen selection strategy translates into a clear set of development priorities, depending on the clinical question your product aims to solve.
- If your primary focus is maximizing population-wide sensitivity and specificity: Build the core of your kit around a high-purity recombinant human tTG antigen for IgA detection, complemented by deamidated gliadin peptides for both IgA and IgG to capture the full spectrum of antibody responses.
- If your primary focus is preventing false negatives in high-risk or pediatric populations: Ensure your kit includes IgG anti-tTG and IgG anti-DGP assays, along with a total IgA measurement step, to detect cases masked by selective IgA deficiency or immature IgA production.
- If your primary focus is cost-efficiency without sacrificing accuracy: Replace native gliadin entirely with a single high-performing DGP antigen blend, pairing it with recombinant tTG to maintain dual-target confidence while reducing development complexity.
A diagnostic assay that faithfully replicates the core disease mechanism—TTG-mediated deamidation—delivers the reliability clinicians need to confidently identify celiac disease without invasive biopsy.
Summary Table:
| Diagnostic Target | Pathophysiological Basis | Key Isotypes | Clinical Performance & Role |
|---|---|---|---|
| Recombinant h-tTG | Primary autoantigen driving autoimmune cascade | IgA, IgG | Gold Standard: Sensitivity >90%, Specificity >99% for first-line screening. |
| Deamidated Gliadin Peptides (DGP) | Synthetic replication of TTG-deamidated gluten immunogenic epitopes | IgA, IgG | High Specificity (~99% for IgG): Superior performance in young children (<3 yrs). |
| Dual IgA/IgG Panel | Solves total IgA deficiency (1 in 600) false-negative risk | Combined | Essential Safety Net: Ensures accurate diagnosis across all patient profiles. |
| Native Gliadin (Deprecated) | Unmodified substrate lacking key negative charges for HLA binding | N/A | Avoid: Low specificity and high false-positive rates due to non-specific binding. |
Developing high-performance celiac diagnostic kits? CamelBio provides diagnostic manufacturers, clinical labs, and research institutes with one-stop access to top-tier IVD raw materials (including high-purity recombinant human tTG and customized DGP antigens), technical services, and consulting—covering every stage from concept to clinic.
Enhance your assay's sensitivity and specificity while accelerating time-to-market. Contact CamelBio today to request antigen samples or discuss your development pipeline with our IVD experts!